Once the national regulatory review has been conducted and the company receives approval, it will initiate two Phase 2b studies to determine the depth of hepatitis B surface antigen (HBsAg) reduction following ARC-520 injection in combination with entecavir or tenofovir in patients with chronic immune active HBV infection. Read more here: streetreport.co/arrowhead-r...
Arrowhead Research Corp Files Investi... - HFI Connect - Hep...
Arrowhead Research Corp Files Investigational New Drug Application for Hepatitis B Treatment
Written by
NAhluwalia
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Just found out I have Hep B and have red spots all over is that normal.
Hello everyone, I recently went to the doctors for food poisoning and found out I have typhiod and...
